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Abstract
Background: While chronic kidney disease (CKD) is com-
mon in resistant hypertension (RHTN), prior studies 
 evaluating mineralocorticoid receptor antagonists excluded 
patients with reduced kidney function due to risk of hyper-
kalemia. AMBER (ClinicalTrials.gov identifier NCT03071263) 
will evaluate if the potassium-binding polymer patiromer 
used concomitantly with spironolactone in patients with 
RHTN and CKD prevents hyperkalemia and allows more per-
sistent spironolactone use for hypertension management. 
Methods: Randomized, double-blind, placebo-controlled 
parallel group 12-week study of patiromer and spironolac-
tone versus placebo and spironolactone in patients with un-
controlled RHTN and CKD. RHTN is defined as unattended 
systolic automated office blood pressure (AOBP) of 
 135–160 mm Hg during screening despite taking ≥3 antihy-
pertensives, including a diuretic, and an angiotensin-con-
verting enzyme inhibitor or an angiotensin receptor blocker 
 (unless not tolerated or contraindicated). The CKD inclusion 
criterion is an estimated glomerular filtration rate (eGFR) of 
25 to ≤45 mL/min/1.73 m2. Screening serum potassium 
must be 4.3–5.1 mEq/L. The primary efficacy endpoint is the 
between-group difference (spironolactone plus patiromer 
versus spironolactone plus placebo) in the proportion of pa-
tients remaining on spironolactone at Week 12. Results: 
Baseline characteristics have been analyzed as of March 
2018 for 146 (of a targeted 290) patients. Mean (SD) baseline 
age is 69.3 (10.9) years; 52.1% are male, 99.3% White, and 
47.3% have diabetes. Mean (SD) baseline serum potassium 
is 4.68 (0.25) mEq/L, systolic AOBP is 144.3 (6.8) mm Hg, 
eGFR is 35.7 (7.7) mL/min/1.73 m2. Conclusion: AMBER will 
define the ability of patiromer to facilitate the use of spi-
ronolactone, an effective antihypertensive therapy for pa-
tients with RHTN and CKD. © 2018 The Author(s) 
Published by S. Karger AG, Basel
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
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Background and Study Rationale
Resistant hypertension (RHTN) is defined by blood 
pressure remaining above the treatment goal despite 
treatment with optimally tolerated doses of 3 antihyper-
tensive agents from different drug classes, including a 
 diuretic [1]. In addition to a diuretic, most practice guide-
lines recommend treatment with an angiotensin- 
converting enzyme inhibitor (ACEI) or angiotensin 
receptor blocker (ARB) and a calcium channel blocker in 
these patients [2–7]. Treatment-RHTN remains a signifi-
cant medical problem, with prevalence estimates of up to 
8% among treated hypertensive patients evaluated by 
24-h ambulatory blood pressure monitoring [8], and ap-
proaching 50% in specific cohorts, such as patients with 
chronic kidney disease (CKD) with proteinuria [9, 10].
Despite the inhibition of the renin-angiotensin- 
aldosterone system with an ACEI or ARB, RHTN may 
result from abnormal sodium retention caused by aldo-
sterone breakthrough, a phenomenon affecting 30–40% 
of patients treated with an ACEI or ARB over 1 year [11]. 
In non-epithelial tissues, aldosterone-induced activation 
of mineralocorticoid receptors in the presence of high ex-
tracellular sodium levels promotes tissue inflammation 
and injury, which may contribute to the progression of 
CKD and cardiovascular disease [12–14]. Together, these 
observations provide the rationale for use of aldosterone 
antagonists (mineralocorticoid receptor antagonists 
[MRAs]) such as spironolactone in patients with RHTN 
[15].
Two meta-analyses of clinical and observational stud-
ies conducted from 2002 to 2013 concluded that spirono-
lactone effectively reduces blood pressure in patients with 
RHTN, although the studies were often nonrandomized, 
and comparison between other treatment options was 
limited [16, 17]. Subsequent to these meta-analyses, the 
PATHWAY-2 study, a randomized, double-blind, cross-
over study, evaluated patients with RHTN rotated through 
12 weeks of add-on treatment with spironolactone, biso-
prolol, doxazosin, or placebo [18]. Spironolactone was 
found to be significantly more effective than the other 
drugs in reducing blood pressure, regardless of plasma 
renin levels, although most effective in those with the 
lowest renin levels. Most RHTN studies evaluating spi-
ronolactone have excluded patients with significant CKD 
due to the risk of hyperkalemia. In a meta-analysis, the 
addition of spironolactone to an ACEI or ARB doubled 
the risk of hyperkalemia in patients with mild to moder-
ate CKD, which was dependent on baseline estimated 
glomerular filtration rate (eGFR), serum potassium (K+) 
level, drug dose, and concomitant medications [19]. Sim-
ilar findings were reported in an observational study, 
where addition of an MRA to a diuretic-renin-angioten-
sin-aldosterone system inhibitor regimen was most likely 
to cause hyperkalemia in patients with baseline eGFR 
≤45 mL/min/1.73 m2 and serum K+ > 4.5 mEq/L [20]. The 
development of potassium binders with improved toler-
ability may allow for increased persistence of MRAs in 
CKD patients with RHTN by reducing the risk of hyper-
kalemia.
Patiromer is a sodium-free, non-absorbed, K+-binding 
polymer used for lowering serum K+ in patients with 
 hyperkalemia [21, 22]. Previously, patiromer prevented 
hyperkalemia in spironolactone-treated heart failure 
 patients with eGFR < 60 mL/min/1.73 m2 and a history of 
hyperkalemia [23]. These findings in a heart failure pop-
ulation support the evaluation of patiromer as a therapy 
to prevent hyperkalemia when RHTN patients are treated 
with spironolactone, since its use in CKD is often limited 
by the risk of hyperkalemia [6].
Methods
This is a randomized, double-blind, placebo controlled, paral-
lel group study of patiromer for the enablement of spironolactone 
use for blood pressure control in patients with RHTN and CKD 
(AMBER; ClinicalTrials.gov identifier NCT03071263). This mul-
ticenter, multinational study will compare patiromer versus pla-
cebo with concomitant spironolactone in patients with RHTN and 
CKD. AMBER is ongoing, and began enrolling patients on January 
23, 2017. The study consists of a screening/run-in period of up to 
4 weeks, a double-blind treatment period of 12 weeks, and a follow-
up visit scheduled 2 weeks after the treatment period or early ter-
mination (Fig. 1).
Study Oversight and Eligibility
The study is being conducted in accordance with the Declara-
tion of Helsinki and in compliance with International Conference 
for Harmonisation E6 Guidelines for Good Clinical Practice and 
all applicable local and national regulations governing the conduct 
of human clinical trials. Study sites must obtain the approval from 
the Institutional Review Board/Independent Ethics Committee 
before performing any study-related procedures, and all patients 
must provide written informed consent before participating. 
Patients ≥18 years old with uncontrolled RHTN and an eGFR 
of 25–45 mL/min/1.73 m2 are eligible to participate in the study. 
Complete lists of inclusion and exclusion criteria are given in on-
line supplemental Tables 1, 2 (for all online suppl. material, see 
www.karger.com/doi/10.1159/000492622). Prohibited medica-
tions are listed in online supplemental Table 3.
The screening/run-in period consists of 4 visits (S1, S2, S3, and 
S4), each separated by 4 to 10 days, and is designed to ensure that 
patients are on stable doses of medication, have true treatment-
RHTN, can properly and reliably use a home blood pressure (HBP) 
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monitor, and meet all inclusion criteria. At each visit after the ini-
tial screening visit, 2 types of office blood pressure measurements 
will be made on the patient: Automated office blood pressure 
(AOBP) and self-measured blood pressure (SMBP). 
Automated Office Blood Pressure
AOBP will be performed by an oscillometric blood pressure 
monitoring device (Intellisense® HEM-907; Omron Healthcare 
Inc., Kyoto, Japan). AOBP will be measured in triplicate. The de-
vice is programmed to allow a 5-min rest period before initiating 
the sequence of triplicate measurements, with a 1-min interval be-
tween each measurement. The site staff leaves the room for these 
automated measurements.
Self-Measured Blood Pressure
At the first visit, patients are provided with an HBP monitor 
(Tel-O-Graph®, I.E.M. GmbH, Stolberg, Germany). Patients are 
trained in its use, and are instructed to measure HBP in tripli-
cate  twice daily after 5 min of seated rest at the same times 
each day (e.g., 8: 00 am and 8: 00 pm). For each scheduled office 
visit,  patients are instructed to bring their HBP monitor with 
them.  Immediately following the measurement of AOBP, pa-
tients will then take SMBP in triplicate before site staff returns to 
the room. If a patient does not bring their HBP device, then only 
AOBP will be taken during that visit (SMBP data will be recorded 
as missing).
Treatment Assignment
Patients meeting all eligibility criteria at the final screening vis-
it will be stratified by the local K+ measurement (4.3 to < 4.7 vs. 4.7 
to 5.1 mEq/L) and history of diabetes (yes versus no), then ran-
domized (1: 1) to receive patiromer or placebo in addition to open-
label spironolactone. The blinded study drug will be provided in 
packets as a powder for oral suspension, with each packet contain-
ing patiromer (4.2 g) or microcrystalline cellulose placebo. The 
treatment assignment will be determined via an interactive web 
response system, with study personnel blinded to the results. All 
randomized patients will be instructed when to take spironolac-
tone, patiromer or placebo, and their antihypertensive medica-
tions, starting on Day 1 of the randomized treatment period. Visits 
during the treatment period are weekly (Weeks 1–4) and then bi-
weekly (Weeks 6–12). 
Spironolactone
Open-label spironolactone will be started at 25 mg once daily 
and increased to 50 mg once daily at Week 3 in patients with sys-
tolic AOBP ≥120 mm Hg and K+ ≤5.1 mEq/L (as shown in the 
spironolactone dosing algorithm in Fig. 2). Patients with systolic 
AOBP ≥120 mm Hg and serum K+ > 5.1 mEq/L at Week 3 will con-
tinue on the 25-mg spironolactone dose until the first subsequent 
visit at which serum K+ is ≤5.1 mEq/L (and systolic AOBP remains 
≥120 mm Hg), at which time the spironolactone dose will be raised 
to 50 mg. Patients with systolic AOBP < 120 mm Hg at Week 3 will 
continue on the 25-mg dose. At any visit, if a patient experiences 
hypotensive symptoms, with systolic AOBP < 120 mm Hg, or if 
systolic AOBP is < 100 mm Hg, the spironolactone dose may be 
reduced to 25 mg every other day or discontinued at the investiga-
tor’s discretion. If spironolactone is discontinued, double-blind 
study drug (patiromer or placebo) will be discontinued at the same 
time. Patients who discontinue spironolactone and patiromer/pla-
cebo for any reason will remain in the study and be treated with 
standard medical care based on the investigator’s clinical judg-
ment. Dietary counseling will also be provided at each visit in ac-
cordance with the standard practices of the investigator.
Patiromer
Patients will initiate study medication with 2 packets daily 
 taken with food at least 3 h before or 3 h after other medications, 
including spironolactone. Dosing adjustments will be made at in-
tervals of ≥1 week in 2-packet/day increments upward for local 
serum K+ > 5.1 mEq/L and downward for serum K+ < 4.0 mEq/L 
(as shown in the patiromer/placebo dosing algorithm in Fig. 3). 
The maximum daily dosage is 6 packets; the minimum is 0 packets. 
Patients who develop serum K+ ≥5.5 mEq/L that cannot be 
 managed with blinded patiromer/placebo dosage escalation will 
discontinue spironolactone and patiromer/placebo treatments. 
These patients will remain in the study and will be followed per 
protocol, with hyperkalemia treated using standard of care.
Spironolactone + blinded patiromer
CKD pts with resistant hypertension
• Systolic AOBP 135–160 mm Hg
• eGFR 25–45 mL/min/1.73 m2
• Serum K+ 4.3–5.1 mEq/L
Additional antihypertensive medication as needed
Spironolactone + blinded placebo
R
a
n
d
o
m
i
z
e
Day 1: start spironolactone 25 mg once daily, 8.4 g/day patiromer or placebo
Visit: S1 S2 S3 S4 Wk1 Wk2 Wk3 Wk4 Wk6 Wk8 Wk10 Wk12 F/U
Screening/run-in,
up to 4 weeks* 
Double-blind treatment period,
12 weeks
Safety follow-up,
2 weeks
Fig. 1. AMBER study design. AOBP, automated office blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtra-
tion rate; HBP, home blood pressure. * To ensure eligibility criteria, stable medication, and competent use of HBP monitor.
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Study Endpoints
The primary endpoint is the difference in the proportion of 
patients remaining on spironolactone at Week 12 between treat-
ment groups (spironolactone plus patiromer versus spironolac-
tone plus placebo). A key secondary endpoint is the difference in 
systolic AOBP from baseline to Week 12 (or to the last available 
AOBP before addition of any new antihypertensive medications or 
change in any of the baseline antihypertensive medications) be-
tween treatment groups. Other endpoints include the following: 
within-group changes in systolic AOBP from baseline to Week 12, 
changes in K+ levels over time measured by a central laboratory 
and by local laboratories, proportion of patients with serum K+ 
≥5.5 mEq/L, average daily dose and cumulative dose of spirono-
lactone, time to discontinuation of spironolactone, and changes in 
albuminuria (urine albumin to creatinine ratio) from baseline to 
Week 12. HBP data will be examined via exploratory analysis. In 
addition, the EuroQol Group 5-domain 5-level (EQ-5D-5L) ques-
tionnaire, a generic patient-reported instrument for measuring in-
cremental changes in health, will be collected at baseline and Week 
12 (or early termination) [24]. The questionnaire is composed of 
5 questions representing 5 health domains: mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depression.
Sample Size Determination
AMBER plans to enroll approximately 290 patients at 60 sites in 
the United States, South Africa, the United Kingdom, France, 
 Germany, Croatia, Hungary, Georgia, and Ukraine. The planned 
sample size ensures that at least 280 patients will be available for the 
Asymptomatic
Continue 25 mg once daily
Symptomatic
Hypotension*
Systolic AOBP
<100
≥120
≥120
<120
<120
<120
Any
Any
Any
Any
>5.1
≤5.1
≤5.1
>5.1
Week 1
and
Week 2
Week 3
Week 4
to
Week 10
Increase to 50 mg once daily 
Continue 25 mg once daily
Asymptomatic
Symptomatic
hypotension*
Systolic AOBP
<100
If currently on 50 mg once daily: continue this dose
If currently on 25 mg once daily: 
If currently on 25 mg every other day: 
increase to 50 mg once daily
increase to 25 mg once daily
Continue current spironolactone dose, refer to patiromer/placebo algorithm per Figure 3
Asymptomatic Continue current dose
Symptomatic
hypotension*
Systolic AOBP
<100
Decrease to next lower dose, or decrease to 25 mg every other day, 
or discontinue (per Pl judgment)†
Decrease to next lower dose, or decrease to 25 mg every other day,
or discontinue (per Pl judgment)†
Continue 25 mg once daily
Continue 25 mg once daily
Decrease to 25 mg every other day, or discontinue (per Pl judgment)†
Decrease to 25 mg every other day, or discontinue (per Pl judgment)†
Decrease to 25 mg every other day, or discontinue (per Pl judgment)†
Visit
Systolic AOBP
(mm Hg)
Local K+
(mEq/L) Titration recommendation
Decrease to 25 mg every other day, or discontinue (per Pl judgment)†
≥120
≥120
Fig. 2. Spironolactone dosing algorithm. AOBP, automated office blood pressure; K+, potassium; PI, principal investigator. * Investiga-
tor determined. † If spironolactone is discontinued, patiromer/placebo must be discontinued at the same time.
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primary endpoint analysis, allowing for the possibility that up to 10 
randomized patients will not take any study medication. A cohort 
of 280 patients provides 90% power to detect a difference between 
treatment groups of ≥20% in the proportion of patients remaining 
on spironolactone at Week 12 at an α = 0.05. Assuming a dropout 
rate of 15%, the sample size also provides approximately 80% power 
to detect a 4 mm Hg difference between treatment groups in change 
in systolic AOBP from Baseline to Week 12 (or to the last available 
AOBP before addition of any new antihypertensive medications or 
change in any of the baseline antihypertensive medications). 
Monitoring Changes in Renal Function
Acute reductions in GFR have been reported with the initiation 
of spironolactone, similar to those observed when starting an 
ACEI or ARB, and have been attributed to transient changes in 
glomerular hemodynamics [6, 25]. Similar to renin-angiotensin 
blocker agents, these changes typically do not impact long-term 
renal function [26–28]. Therefore, subjects will be monitored for 
changes in renal function, especially during periods of medication 
changes or adjustments. Kidney Disease Outcomes Quality Initia-
tive (KDOQI) recommendations for the detection and manage-
ment of early decreases in GFR when initiating ACEIs or ARBs will 
be considered in this study for spironolactone when reductions in 
renal function occur [29].
Extrapolating from the KDOQI guidelines for ACEI/ARBs, in 
this study, we define an early decline in eGFR as a > 15% reduction 
from baseline within 4 weeks of starting spironolactone; no change 
in spironolactone dose is needed for decreases in eGFR ≤30%. 
However, for decreases in eGFR of 30–50%, the spironolactone 
dose should be decreased and eGFR monitored weekly; spirono-
lactone should be discontinued if eGFR does not return to within 
30% of baseline within 4 weeks. For eGFR decreases > 50%, spi-
ronolactone should be discontinued and eGFR monitored weekly 
until it returns to within 15% of baseline.
Assessments
AOBP will be measured at all visits. These measurements will 
be performed before other scheduled assessments except for the S4 
and Week 12 visits, when EQ-5D-5L will be administered first. A 
24-h urine collection will be performed prior to the baseline visit, 
and the first 3 morning urine samples will be collected at baseline 
and periodically throughout the study for central laboratory as-
sessment of albuminuria (urine albumin-to-creatinine ratio). Se-
rum K+ will be assessed locally and by a central laboratory at all 
study visits. The central laboratory will analyze all other labora-
tory tests, including serum and urine chemistry, creatinine, and 
hematology. N-terminal pro b-type natriuretic peptide levels will 
also be measured as a biomarker of cardiac stress. Spironolactone 
levels in blood will be measured by mass spectrometry. Adverse 
events will be monitored at all visits, and physical examinations 
and 12-lead electrocardiograms will be performed at the S1 and 
Week 12 visits. 
Local K+ (mEq/L) Titration recommendation (minimum dose is zero packets/day, maximum 6 packets/day)
<4.0
≥4.0 to 5.1
>5.1 to <5.5
≥5.5 to <6.0
≥6.0
Decrease by at least
2 packets once daily*
Continue current dose
Continue max dose
Increase by 2
packets per day†
Remeasure K+ levels
within 1 day
Increase by 2
packets per day†
Reassess within 1 week
Assess at next schedule visit
Reassess within 1 week
Reassess within 1 week
If K+ still ≥5.5, discontinue
spironolactone and
patiromer/placebo‡
Reassess within 1 week
Dose may be escalated at a
subsequent visit if K+ is >5.1 
Reassess within 3 days
Continue current dose
Reassess within 1 week
Discontinue spironolactone
and patiromer/placebo;‡
Reassess within 1 week
Repeat K+ measurement
within 1 day to confirm If repeat K+ is ≥6.0, discontinue spironolactone and patiromer/
placebo;‡ Reassess within 1 week
If repeat K+ is <6.0, follow instruction for ≥5.5 to <6.0 above
On max
dose
On max
dose
Not on 
max
dose
Not on 
max
dose
K+<5.5
K+≥5.5
Fig. 3. Patiromer dosing algorithm. K+, potassium. * Each packet contains patiromer (4.2 g) or microcrystalline cellulose placebo. † All 
dose increases should be made no less than 1 week apart. ‡ After discontinuation, hyperkalemia may be treated at any time using stan-
dard of care per Investigator judgment.
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Statistical Plan
The primary endpoint will be compared between treatment 
groups using the Cochran-Mantel-Haenszel test, stratified by 
baseline K+ category (4.3 to < 4.7 vs. 4.7 to 5.1 mEq/L) and pres-
ence/absence of diabetes mellitus. The secondary endpoint will be 
analyzed using an analysis of covariance (ANCOVA) model, with 
baseline systolic AOBP as a covariate and baseline serum K+ and 
presence/absence of diabetes mellitus as categorical factors. The 
primary and secondary endpoints will also be evaluated in several 
pre-specified subgroups of interest, including gender, age group 
(<65 vs. ≥65 years), and diabetes (yes vs. no). Change in systolic 
AOBP at Week 12 will be analyzed with an ANCOVA model for 
patients with non-missing systolic AOBP at both baseline and 
Week 12, and additionally using a repeated measures mixed mod-
el that includes all patients with at least one post-baseline measure-
ment of systolic AOBP. These models will also include baseline 
systolic AOBP as a covariate and presence/absence of diabetes 
mellitus and baseline serum K+ as categorical factors. Time to dis-
continuation of spironolactone will be analyzed using Kaplan-
Meier methods, and average daily and cumulative dose of spirono-
lactone will be analyzed using ANCOVA methods. Change in al-
buminuria, serum K+ levels, EQ-5D-5L questionnaire results, and 
safety parameters will be summarized descriptively. 
Characteristics of Randomized Patients
Baseline characteristics, analyzed as of March 2018 for 
146 randomized patients (of a targeted 290 patients) who 
had completed through Week 12, are shown in Table 1. 
Overall, the mean (SD) baseline age is 69.3 (10.9) years, 
with 52.1% male, and 99.3% of White race. Roughly 
half  of the patient population (47.3%) has diabetes 
 mellitus, with a mean time since the diagnosis of 13.4 
years; 50.7% have a history of heart failure. The mean 
(SD)  baseline values are as follows: for eGFR, 35.7 (7.7) 
mL/min/1.73 m2, for serum K+, 4.68 (0.25) mEq/L, for 
systolic AOBP, 144.3 (6.8) mm Hg, and for diastolic 
AOBP, 79.7 (12.1) mm Hg.
Discussion
Spironolactone has been shown to reduce blood pres-
sure in the general RHTN population [16, 17], and in 
RHTN patients with heart failure with preserved ejection 
fraction [30]. It has been found to be a more effective BP-
lowering agent compared with other medication classes, 
as demonstrated in PATHWAY-2 [18]. Despite having a 
high prevalence of RHTN, patients with clinically signifi-
cant CKD are typically excluded from treatment trials, as 
these patients have higher risk and often develop clini-
cally significant hyperkalemia when exposed to renin-an-
giotensin blocking agents and MRAs. Hence, the CKD 
population with RHTN remains understudied and un-
derserved. 
The AMBER study design was based on the hypothesis 
that concomitant use of spironolactone and patiromer in 
CKD patients with RHTN will better manage the risk of 
hyperkalemia, and thereby allow more persistent use of 
spironolactone – which ultimately would lead to improved 
blood pressure control. A unique aspect of the AMBER 
trial is that it will measure AOBP while the patient is unat-
Table 1. Baseline characteristics of randomized patients*
Characteristic Randomized
(n = 146)
Age, years, mean (SD)
≥65 at informed consent, n (%)
69.3 (10.9)
104 (71.2)
Male, n (%) 76 (52.1)
White race, n (%) 145 (99.3)
Ethnicity, n (%)
Hispanic or Latino
Non-Hispanic and non-Latino
Not reported
12 (8.2)
133 (91.1)
1 (0.7)
Diabetes mellitus, n (%)
Time since diagnosis, years, mean (SD)
69 (47.3)
13.4 (8.3)
Serum potassium (local), mEq/L, mean (SD) 4.68 (0.25)
eGFR, mL/min/1.73 m2, mean (SD) 35.7 (7.7)
Automated office blood pressure, mm Hg, mean (SD)
Systolic
Diastolic
144.3 (6.8)
79.7 (12.1)
Antihypertensive medications, n (%)
Beta blockers
Calcium channel blockers
Non-RAASi diuretics
RAASi
Other
89 (61.0)
105 (71.9)
132 (90.4)
145 (99.3)
34 (23.3)
History of hyperkalemia associated with the 
use of ACEi, ARB, or MRA, n (%) 2 (1.4)
Cardiac disorders, n (%)
Atrial fibrillation
Atrial flutter
88 (60.3)
14 (9.6)
1 (0.7)
History of stroke or cerebrovascular accident, n (%) 18 (12.3)
History of myocardial infarction, n (%) 31 (21.2)
History of heart failure, n (%)
Ejection fraction, mean (SD)
Preserved ejection fraction, n (%)
Reduced ejection fraction, n (%)
Unknown
74 (50.7)
47.5 (9.6)
24 (16.4)
36 (24.7)
14 (9.6)
NYHA class, n (%)
I
II
III
11 (7.5)
55 (37.7)
8 (5.5)* Analyzed as of March 2018 for 146 randomized patients (of a targeted 
290 patients) who had completed through Week 12.
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin re-
ceptor blocker; eGFR, estimated glomerular filtration rate; MRA, mine-
ralocorticoid receptor antagonist; NYHA, New York Heart Association; 
RAASi, renin-angiotensin-aldosterone system inhibitor; SD, standard de-
viation.
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tended in the clinical setting, thereby minimizing potential 
“white coat hypertension”. This methodology was used in 
most patients in the SPRINT trial and the values were cor-
related with ambulatory blood pressure during that study 
[31]. The values from this methodology will lead to a more 
precise diagnosis of RHTN. At the time the study was be-
gun, the gold  standard for defining hypertension was the 
awake ambulatory blood pressure. AOBP readings have 
been shown to be equivalent, and so a cut point of 135 mm 
Hg was used as had been used for ambulatory BP [4, 32, 
33]. Although the upper limit of automated office systolic 
blood pressure of 160 mm Hg excludes patients with more 
severe RHTN, it was selected because higher systolic AOBP 
would likely compel  investigators to add additional antihy-
pertensive medications during the treatment period if 
blood pressure  remained uncontrolled, which could con-
found interpretation of study results. 
Eligibility also requires an eGFR of 25–45 mL/
min/1.73 m2 (mean of 2 screening values). Risk of hyper-
kalemia during spironolactone therapy is substantially 
 increased with eGFR < 45 mL/min/1.73 m2 [20]. Further-
more, spironolactone is contraindicated for patients with 
acute renal insufficiency or significant impairment of re-
nal excretory function [34]. To minimize patient risk, lab-
oratory assessment will be performed regularly through 
the trial, including serum creatinine, eGFR, and potassium 
measurements. An initial decrease in renal function is ex-
pected following the addition of spironolactone to a back-
ground regimen of 3 antihypertensive agents that include 
a diuretic and renin-angiotensin blocking agent. Investi-
gators are recommended to follow KDOQI guidelines for 
the detection and management of early decreases in eGFR. 
According to KDOQI recommendations, significant de-
clines from baseline in eGFR > 30% may require dose ad-
justment or discontinuation of spironolactone [29].
An important consideration for the trial design was 
the use of 24-h ambulatory blood pressure monitoring. 
While we recognize the value of this technique, we rea-
soned that given frequent titrations of the drug and 
 downstream blood pressure measurements, we may have 
missing data if we required frequent 24-h ambulatory 
blood pressure monitoring. Given that the pattern of 
missing data may not be random, it may introduce bias in 
the study design. In view of the important relationships 
observed between AOBP and CV outcomes, we chose this 
as the primary endpoint in this trial.
If the primary endpoint is positive in the AMBER 
study, it would indicate that patiromer effectively en-
abled persistent spironolactone use in CKD patients 
by maintaining serum K+ in a normal range and mini-
mizing the risk of hyperkalemia. If the secondary end-
point assessing reductions in blood pressure is also pos-
itive, it would indicate that the ability of patiromer to 
permit chronic spironolactone use translates into bet-
ter  blood pressure control, extending previous find-
ings from PATHWAY-2 and other studies to the CKD 
population with RHTN [18, 30, 35–37]. Finally, because 
albuminuria is a marker of cardiovascular and renal out-
comes [38–40], positive reductions in albuminuria fa-
voring the spironolactone and patiromer arm may set the 
stage for a renal outcomes study with these agents. 
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